A Study of a Novel Precision Medicine Approach For Obesity

NCT06814938 · Recruiting

Last updated 2026-05-28

This clinical trial is testing a new personalized treatment method for obesity in adults over a 24-week period.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 135 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-02 · est. completion 2028-11

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06814938 ↗

Description as written by the study sponsor.

This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

Semaglutide Drug

2.4 mg subcutaneous weekly
Placebo Drug

Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly

Main thing measured	Change in Total Body Weight at 24 weeks
Sponsor	Mayo Clinic
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06814938 ↗